{
  "1": {
    "premise": "Outcome Measurement: Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab. Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL within 10 days after the first dose of denosumab. For all CSC values, if albumin was ≤ 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 × (4 - serum albumin [g/dL])). Time frame: 10 days. Results: Overall Number of Participants Analyzed: 33. Unit of Measure: percentage of participants: 63.6% (95% CI: 45.1 to 79.6).",
    "statement": "This outcome proves that Denosumab is effective despite no comparison group.",
    "label": false
  },
  "2": {
    "premise": "Adverse Events 1: Total: 4/11 (36.36%). Blood bilirubin increased 1/11 (9.09%), Febrile neutropenia 1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia (Sinus tachycardia) 1/11 (9.09%), Sepsis 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09%).",
    "statement": "Adverse event data provide information about how effective the treatment is.",
    "label": false
  },
  "3": {
    "premise": "Outcome Measurement: Proportion of Patients With Blood Pressure <140/90 mmHg at Week 12. Blood pressure was measured at baseline and at week 12 after starting amlodipine. Time Frame: 12 weeks. Results: 70.2% of 47 patients had blood pressure <140/90 mmHg at week 12. 95% CI: 56.4 to 81.8.",
    "statement": "This outcome proves that Amlodipine is effective despite no comparison group.",
    "label": false
  },
  "4": {
    "premise": "Outcome Measurement: Percentage of Patients With HbA1c <7% After 24 Weeks of Treatment With Sitagliptin. HbA1c levels were assessed at baseline and at the end of 24 weeks. Time Frame: 24 weeks. Results: 58.3% of 60 patients achieved HbA1c <7%. 95% CI: 44.9 to 70.9.",
    "statement": "This outcome proves that Sitagliptin is effective despite no comparison group.",
    "label": false
  },
  "5": {
    "premise": "Adverse Events Summary: Total: 5/15 (33.33%). Elevated liver enzymes 2/15 (13.33%), Nausea 1/15 (6.67%), Thrombocytopenia 1/15 (6.67%), Bradycardia 1/15 (6.67%), Hypokalemia 1/15 (6.67%).",
    "statement": "Adverse event data provide information about how effective the treatment is.",
    "label": false
  },
  "6": {
    "premise": "Adverse Events Summary: 6/20 (30.00%). Headache 3/20 (15.00%), Fatigue 2/20 (10.00%), Rash 1/20 (5.00%). All adverse events were Grade 1 or 2.",
    "statement": "Adverse event data provide information about how effective the drug is.",
    "label": false
  },
  "7": {
    "premise": "Treatment-Emergent Adverse Events: 7/18 (38.89%). Anemia 2/18 (11.11%), Hypertension 2/18 (11.11%), Dizziness 1/18 (5.56%), Insomnia 1/18 (5.56%), Constipation 1/18 (5.56%).",
    "statement": "Adverse event data provide information about how effective the treatment is.",
    "label": false
  },
  "8": {
    "premise": "Outcome: Proportion of patients achieving LDL cholesterol <100 mg/dL after 8 weeks of atorvastatin therapy. Results: 52.4% (11/21) of patients achieved the target. Time frame: 8 weeks.",
    "statement": "This outcome proves that Atorvastatin is effective despite no comparison group.",
    "label": false
  },
  "9": {
    "premise": "Outcome: Rate of wound healing at Day 14 following topical application of silver sulfadiazine. 40% (8/20) of wounds showed full epithelialization by Day 14. Time frame: 14 days.",
    "statement": "This outcome proves that Silver sulfadiazine is effective despite no comparison group.",
    "label": false
  },
  "10": {
    "premise": "Outcome: Percentage of participants with pain reduction ≥30% on a 10-point scale at Week 6 following treatment with oral tramadol. 65% (13/20) met the pain reduction threshold. No control group included.",
    "statement": "This outcome proves that Tramadol is effective despite no comparison group.",
    "label": false
  }
}
